Lumos Diagnostics (LDX.AX)股价飙升，价值翻倍至0.080澳元。这一惊人涨幅创下自2023年7月以来最大日内百分比增幅。医疗科技公司签署了针对FebriDx产品的美国分销和供应协议，潜在价值高达3.17亿美元。FebriDx作为一种快速点检测试，通过手指采血帮助临床医生区分细菌性和非细菌性急性呼吸道感染。协议与总部位于香港的PHASE Scientific International达成。交易量激增至约1580万股，远超30天平均的66.3万股。年初至今，股价已上涨108.6%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.